Novel Method to Correct Altered Synaptic Signaling in Autism and Intellectual Disability
Invention type: Technology
/
Case number: #18383PHJ
Disclosed herein are novel methodologies of treating fragile X syndrome and related disorders by inhibiting mGlu5-relevant signaling pathways via the reduction of β-arrestin2 protein levels or the diminution of mGlu5 and β-arrestin2 protein interactions.
Researchers
Mark Bear
/ Benjamin Auerbach
/ Laura Stoppel
/ Robert Lefkowitz
Departments: Department of Brain and Cognitive Sciences
Technology Areas: Therapeutics: Proteins & Antibodies
Impact Areas: Healthy Living
-
methods of treating fragile x syndrome and related disorders
United States of America | Granted | 10,682,397
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.